SUBMISSION OF ARTICLES

All Articles and Material should be submitted on-line via EES http://ees.elsevier.com/tr. Please refer to the 'Tutorial for Authors' located on the EES site for guidance on the electronic submission process.

If you have any general queries, please contact the Editorial Office: Email: thrombosis-research@ioks.uio.no

For Review Article submissions please contact Senior Associate Editor: Dr Nigel Key, University of North Carolina, 932 Mary Ellen Jones Building, CB #7035, Chapel Hill, NC 27599, USA; Email: nigel_key@med.unc.edu

Several categories of manuscripts will be considered for publication.
(1) Original Articles are full length reports of original work. (5-6,000 words)
(2) Review Articles Review Articles constitute a literature review of a particular area and can be clinical or concentrate on a basic science topic. Review Articles are often commissioned but if you would like to submit a proposal, please contact Dr Nigel Key at the above address. Proposals for a series of review articles under one main heading will also be considered. Mini reviews, providing a concise overview of the current research and/or clinical status of the topics under discussion, will also be considered. (6 -7,000 words)
(3) Letters to the Editors-in-Chief. These contributions should be concerned with matters of opinion and criticism on contributions published in the journal and other matters of interest to researchers in our field. (1,500 words)
(4) Editorials provide comments on matters significant to the readers of Thrombosis Research. (1,500 words)
(5) Reports of Scientific Meetings are published from time-to-time. Please contact the Editors-in-Chief regarding these.
(6) Supplement issues may cover various topics in the field of thrombosis and hemostasis. They are approved by the Editors-in-Chief and edited preferably by one of the Editors of Thrombosis Research.
In addition to the above categories various News Items and Announcements will also be considered.(500 words)

Authorship: All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted. Please list up to six authors before using "et al".

Acknowledgements: All contributors who do not meet the criteria for authorship as defined above should be listed in an acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance.

Conflict of interest: At the end of the text, under a subheading "Conflict of interest statement" all authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Role of the funding source: All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Randomised controlled trials
All randomised controlled trials submitted for publication in Thrombosis Research should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart. Please refer to the CONSORT statement website at http://www.consort-statement.org for more information. Thrombosis Research has adopted the proposal from the International Committee of Medical Journal Editors (ICMJE) which require, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. For this purpose, a clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration. Further information can be found at http://www.icmje.org. If a CONSORT flow chart is not included with the submitted manuscript, authors should provide a statement explaining the omission.

Disclosure of clinical trial results
In line with the position of the International Committee of Medical Journal Editors, Thrombosis Research is willing to consider manuscripts which include results posted in the same clinical trials registry in which primary registration resides. It will not consider such postings to be prior publication, providing the results are presented in the form of a brief structured (500 words) abstract or table. However, divulging results in other circumstances (eg, investors' meetings) is strongly discouraged and may jeopardise consideration of the manuscript. Authors should fully disclose all postings in registries of the same or closely related work.

Ethics:
Identifying information, including patients' images, names, initials, or hospital numbers, should not be included in videos, recordings, written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and you have obtained written informed consent for publication in print and electronic form from the patient (or parent, guardian or next of kin where applicable). If such consent is made subject to any conditions, Elsevier must be made aware of all such conditions. Written consents must be provided to Elsevier on request. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note. If such consent has not been obtained, personal details of patients included in any part of the paper and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Supplementary material
Thrombosis Research accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, movies, animation sequences, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article including ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submitted material is directly usable, please ensure that data is provided in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at http://www.elsevier.com/artworkinstructions

Online-only Publication
Thrombosis Research offers authors the opportunity to select online-only publication as their preferred option for publishing their paper in the journal, rather than print publication. If authors wish to do this, their paper will be published online on ScienceDirect as a paginated and fully citable electronic article. It will be listed in the contents page of a printed issue and the full citation and abstract will be published in print. The citation and abstract of the paper will also still appear in the usual abstracting and indexing databases.

Authors will be asked to select which publication option they would prefer when submitting their paper to the Editorial Office. Please note that e-publication is selected at the Editors discretion. Authors will be notified if their manuscript has been selected for e-publication upon acceptance of the manuscript.

FORMATTING INSTRUCTIONS

General Information:
It is the responsibility of the authors to write in standard, grammatical English. Spelling may be British or American, but must be consistent throughout the text, tables and legends to tables and figures. A word count should be provided in the 'Enter Comments' section of EES and on the title page of the manuscript file. Original articles and Review articles should be organised as follows: (a) Title page; (b) Abstract, Keywords, and Abbreviations; (c) Text with the following sections; Introduction, Materials and Methods, Results, Discussion, Acknowledgments; (d) References; (e) Tables; (f) Table Legends and Figure Legends. The pages should be numbered consecutively; the Title page is page 1, the Abstract page 2, etc. throughout the manuscript (including References, Tables, and Legends to Tables and Figures).

(a) Title Page: Identify the category of the communication on top of the page. Include a brief and descriptive Title of the article, the full Name(s) of the Author(s)(in the format First Name, Initials, and Surname) and the Name and Location of the institution where the research was carried out. A word count of the text should include Tables and Legends. Exclude the Abstract and Reference list. The name, postal and email addresses, telephone and fax numbers of the corresponding author should be included at the bottom of the title page as well as, if necessary, additional addresses of other Authors. If the manuscript was presented at a meeting, the name of the organization, the place and the date on which it was read must be indicated.

(b) Abstract Page: The abstract is essential and the most read part of the paper. It should be informative, not descriptive, and should avoid abbreviations except for units of measure. An abstract for a regular article should not exceed 250 words and should end with the principal conclusions of the study. Structured abstracts are encouraged and should use the following headings: Introduction, Materials and Methods, Results and Conclusions.

Keywords and Abbreviations should follow the abstract and be on the same page (or on a separate page if no abstract). List up to 6 key words for subject indexing, preferably to be taken from Index Medicus. List all abbreviations used.

(c) Text of Articles: The text should be arranged as follows: Introduction, without heading, should state the purpose of the investigation and give a short review of pertinent literature.
Materials and methods should be described in detail with appropriate information about patients or experimental animals. Authors should stipulate that informed consent was obtained when applicable to research on humans, with the comment that the study was approved by the institutional Ethics Committee on human research. Manuscripts reporting animal experiments must include the statement that all animals received care in compliance with the American, European, or any other Convention on Animal Care, with the comment that the study was approved by the institutional Ethics Committee. Generic names of drugs and equipment should be used throughout the manuscript with brand names (proprietary name) and the name and location (city, state, country) of the manufacturer in parentheses when first mentioned in the text.
Results should be reported concisely. Results presented either in tables or figures should be commented on in the text.
Discussion is an interpretation of the results and their significance with reference to pertinent work by other authors. It should be clear and concise. The importance of the study and its limitations should be discussed.
Acknowledgments of financial or personal assistance should be placed at the end of the text.

(d) References: Consecutive numbers in square brackets should be used to indicate references in the text, e.g., [1,2], as part of the text and not raised above it.
The full reference should be cited in a numbered list essentially according to the Vancouver Uniform Requirements (5th ed., Ann Intern Med 1997;126(1):36-47).
References should contain names of all authors in small letters (surnames first followed by initials), Title of communication in lower case lettering, Title of Journal [abbreviated according to International Serials Data System-List of Serial title Word Abbreviations, 1985 (ISDS-ISO International Centre, 20 rue Bachaumont, 75002 Paris, France)], year of publication; volume number: first and last page number (see Ref.1).
Reference to Journal Supplement, cf. example (Ref. 2).
References to books should contain Author Name(s) in the same format as above: Title. Publisher's location: Name; Year of publication. page range (see Ref. 3).
References to multi-author books with editor(s) should contain Author Name(s) in the same format as above: Title of contribution. In: Name(s) of editor(s). Title of book. Publisher's location: Name; Year of publication. If necessary page range (see Ref. 4)
For communications which have been accepted for publication, but not yet printed, the reference must contain the journal name and year (see Ref. 5). Material referred to by the phrase "personal communication" or "submitted for publication" are not considered full references and should only be placed in parentheses at the appropriate place in the text, e.g., (Hessel 1997 personal communication).

Examples of references are shown below.
1. Ordljin TM, Shainoff JR, Lawrence SO, and Simpson-Haidaris PJ. Thrombin cleavage enhances exposure of heparin binding domain in the N-terminus of the fibrin beta chain. Blood 1996;88:2050-61.
2. Copley AL. The endoendothelial fibrin lining. Thromb Res 1983;(SV):1-154.
3. Davies JT, Rideal EK. Interfacial Phenomena. New York-London: Academic Press; 1961. p. 110-30.
4. Blomback B. Fibrinogen to fibrin transformation. In: Seegers WH, editor.
Blood Clotting Enzymology. New York-London: Academic Press; 1967. p. 143-215.
5. Leshner AI. Molecular mechanisms of cocaine addiction. N Engl J Med. In Press 1996.

(e) Tables and Figures: Tables and figures are submitted via the online submission system EES with the accompanying article. Each Table should be included on a separate page. Tables should supplement but not duplicate the text. A brief title should be provided for each. Abbreviations used in Tables should be defined. Legends to Tables should be included at the end of the manuscript file. Figures should be in black and white, all details clear enough to permit reproduction, and legible in the actual size in which they should be published. If the number of tables and/or figures is excessive, the author(s) could be asked to eliminate some of them. Authors requesting color figures in the print version of the Journal will be required to share in their production expenses. Thrombosis Research is part of the programme "Colourful e-Products". This allows illustrations that appear in black and white in the print version of the Journal to be included in colour online, in ScienceDirect. Authors wishing to make use of this facility should ensure that the artwork is in an acceptable format (TIFF, EPS, or MS Office files) and at the correct resolution. In addition, for colour online and black and white in print, both colour and black and white artwork (file and/or hard copy as specified above) must be provided. There is no extra charge for authors who participate in this facility. For more detailed specification on submitting electronic illustrations, please see the following webpage: http://www.elsevier.com/locate/authorartwork

Copyright: Upon acceptance of an article, authors will be asked to sign a "Journal Publishing Agreement" (for more information on this and copyright see http://www.elsevier.com/wps/find/authorshome.authors/copyright). Acceptance of the agreement will ensure the widest possible dissemination of information. An email (or letter) will be sent to the corresponding author confirming receipt of the manuscript together with a "Journal Publishing Agreement" form.

If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: contact Elsevier's Rights Department, Philadelphia, PA, USA: Tel. (+1) 215 238 7869; Fax (+1) 215 238 2239; email healthpermissions@elsevier.com. Requests may also be completed online via the Elsevier homepage (http://www.elsevier.com/locate/permissions).

Peer Review: Regular Articles, Review Articles, and Mini-Reviews are subjected to review by two referees. Acceptance is based upon the significance, originality and validity of the material presented. If you are interested in reviewing for the Journal, please contact the Editors-in-Chief.

Revised Manuscripts: When returning a revised manuscript to the Editor, provide a covering letter in the 'Enter Comments' section of Editorial Manager, replying to the Editor's and referees' comments, describing the changes which have been made in the revised version. Highlight the changes in the revised manuscript to facilitate editorial reassessment. Time for revision must never exceed 60 days.

Funding body agreements and policies
Elsevier has established agreements and developed policies to allow authors who publish in Elsevier journals to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit http://www.elsevier.com/fundingbodies

Proofs
One set of page proofs in PDF format will be sent by e-mail to the corresponding author. Elsevier sends PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 available free from http://www.adobe.com/products/acrobat/readstep2.html. Instructions on how to annotate PDF files will accompany the proofs. The exact system requirements are given at the Adobe site: http://www.adobe.com/products/acrobat/acrrsystemreqs.html#70win
If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post.
Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

Author Names
This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed. After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

Offprints:
The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.

© 2013 Elsevier Ltd. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by Elsevier Ltd, and the following terms and conditions apply to their use:

Photocopying Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

For information on how to seek permission visit http://www.elsevier.com/authors/author-rights-and-responsibilities#permissions or call: (+44) 1865 843830 (UK) / (+1) 215 239 3804 (USA).

Derivative Works
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations (please consult http://www.elsevier.com/authors/author-rights-and-responsibilities#permissions).

AudioSlides
The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at http://www.elsevier.com/audioslides. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

Open Access
This journal offers authors two choices to publish their research;

1. Open Access
• Articles are freely available to both subscribers and the wider public with permitted reuse
• An Open Access publication fee is payable by authors or their research funder
2. Subscription
• Articles are made available to subscribers as well as developing countries and patient groups through our access programs (http://www.elsevier.com/access)
• No Open Access publication fee

All articles published Open Access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

Creative Commons Attribution-Non Commercial-ShareAlike (CC BY-NC-SA): for non-commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author’s honor or reputation, and license their new adaptations or creations under identical terms (CC BY NC SA).

Creative Commons Attribution-NonCommercial-NoDerivs (CC-BY-NC-ND): for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

Elsevier has established agreements with funding bodies. This ensures authors can comply with funding body Open Access requirements, including specific user licenses, such as CC-BY. Some authors may also be reimbursed for associated publication fees. Funding bodies.
If you need to comply with your funding body policy you can apply for the CC-BY license after your manuscript is accepted for publication.

To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published Open Access. Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

The Open Access publication fee for this journal is $USD 2,500, excluding taxes.
Learn more about Elseviers pricing policy.

Electronic Storage or Usage
Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article (please consult www.elsevier.com/permissions). Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.

Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.